Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker

Journal of Molecular Diagnostics

Volumn 16, Issue 4, 2014, Pages 467-476

  Giachelia, Manuela ^a   Bozzoli, Valentina ^a   D'Alò, Francesco ^a   Tisi, Maria Chiara ^a   Massini, Giuseppina ^a   Maiolo, Elena ^a   Guidi, Francesco ^a   Cupelli, Elisa ^a   Martini, Maurizio ^a   Larocca, Luigi M ^a   Voso, Maria Teresa ^a   Leone, Giuseppe ^a   Hohaus, Stefan ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GENOMIC DNA; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE; DAPK1 PROTEIN, HUMAN; DEATH ASSOCIATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DAPK1 GENE; DNA METHYLATION; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; GENE; GENETIC MARKER; GENETIC RISK; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PROGRESSION FREE SURVIVAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; VERY ELDERLY; WATCHFUL WAITING; GENETICS; LYMPHOMA, FOLLICULAR; METABOLISM; METHYLATION; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; DEATH-ASSOCIATED PROTEIN KINASES; DNA METHYLATION; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; METHYLATION; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84902952782     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2014.03.003     Document Type: Article

References (41)

1. P. Solal-Céligny, P. Roy, P. Colombat, J. White, J.O. Armitage, R. Arranz-Saez, W.Y. Au, M. Bellei, P. Brice, D. Caballero, B. Coiffier, E. Conde-Garcia, C. Doyen, M. Federico, R.I. Fisher, J.F. Garcia-Conde, C. Guglielmi, A. Hagenbeek, C. Haïoun, M. LeBlanc, A.T. Lister, A. Lopez-Guillermo, P. McLaughlin, N. Milpied, P. Morel, N. Mounier, S.J. Proctor, A. Rohatiner, P. Smith, P. Soubeyran, H. Tilly, U. Vitolo, P.L. Zinzani, E. Zucca, and E. Montserrat Follicular lymphoma international prognostic index Blood 104 2004 1258 1265
2. M. Federico, M. Bellei, L. Marcheselli, S. Luminari, A. Lopez-Guillermo, U. Vitolo, B. Pro, S. Pileri, A. Pulsoni, P. Soubeyran, S. Cortelazzo, G. Martinelli, M. Martelli, L. Rigacci, L. Arcaini, F. Di Raimondo, F. Merli, E. Sabattini, P. McLaughlin, and P. Solal-Céligny Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project J Clin Oncol 27 2009 4555 4562
3. D. O'Shea, C. O'Riain, C. Taylor, R. Waters, E. Carlotti, F. Macdougall, J. Gribben, A. Rosenwald, G. Ott, L.M. Rimsza, E.B. Smeland, N. Johnson, E. Campo, T.C. Greiner, W.C. Chan, R.D. Gascoyne, G. Wright, L.M. Staudt, T.A. Lister, and J. Fitzgibbon The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival Blood 112 2008 3126 3129
4. T. Herold, M.A. Mulaw, V. Jurinovic, T. Seiler, K.H. Metzeler, A. Dufour, S. Schneider, P.M. Kakadia, K. Spiekermann, U. Mansmann, W. Hiddemann, C. Buske, M. Dreyling, and S.K. Bohlander High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature Leuk Lymphoma 54 2013 1652 1657
5. M. Krajnović, M. Radojković, R. Davidović, B. Dimitrijević, and K. Krtolica Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma Med Oncol 30 2013 441
6. A. Janikova, B. Tichy, J. Supikova, K. Stano-Kozubik, S. Pospisilova, L. Kren, I. Vasova, D. Saleh, and J. Mayer Gene expression profiling in follicular lymphoma and its implication for clinical practice Leuk Lymphoma 52 2011 59 68
7. A. Rambaldi, E. Carlotti, E. Oldani, I. Della Starza, M. Baccarani, S. Cortelazzo, F. Lauria, L. Arcaini, E. Morra, A. Pulsoni, L. Rigacci, M. Rupolo, F. Zaja, P.L. Zinzani, T. Barbui, and R. Foa Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma Blood 105 2005 3428 3433
8. C. Hirt, and G. Dolken Quantitative detection of t(14;18)-positive cells in patients with follicular lymphoma before and after autologous bone marrow transplantation Bone Marrow Transplant 25 2000 419 426
9. M. Ladetto, S. Sametti, J.W. Donovan, D. Ferrero, M. Astolfi, M. Mitterer, I. Ricca, D. Drandi, P. Corradini, P. Coser, A. Pileri, J.G. Gribben, and C. Tarella A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients Exp Hematol 29 2001 183 193
10. C.M. Mandigers, J.P. Meijerink, E.J. Mensink, E.L. Tönnissen, K.M. Hebeda, M.J. Bogman, J.M. Raemaekers Interzol (South-East Netherlands Comprehensive Cancer Centers Cooperative Group) Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma Blood 98 2001 940 944
11. E. Paszkiewicz-Kozik, J. Kulik, A. Fabisiewicz, A. Tysarowski, E. Kraszewska, J.A. Siedlecki, and J. Walewski Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma Med Oncol 26 2009 16 21
12. M. Ghielmini, S.F. Schmitz, S.B. Cogliatti, G. Pichert, J. Hummerjohann, U. Waltzer, M.F. Fey, D.C. Betticher, G. Martinelli, F. Peccatori, U. Hess, E. Zucca, R. Stupp, T. Kovacsovics, C. Helg, A. Lohri, M. Bargetzi, D. Vorobiof, and T. Cerny Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule Blood 103 2004 4416 4423
13. M.H. van Oers, E. Tönnissen, M. Van Glabbeke, L. Giurgea, J.H. Jansen, R. Klasa, R.E. Marcus, M. Wolf, E. Kimby, A. Vranovsky, H. Holte, A. Hagenbeek, and B.A. van der Reijden BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study J Clin Oncol 28 2010 2246 5222
14. A. López-Guillermo, F. Cabanillas, T.I. McDonnell, P. McLaughlin, T. Smith, W. Pugh, F. Hagemeister, M.A. Rodríguez, J.E. Romaguera, A. Younes, A.H. Sarris, H.A. Preti, and M.S. Lee Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma Blood 93 1999 3081 3087
15. C. Hirt, F. Schüler, T. Kiefer, C. Schwenke, A. Haas, D. Niederwieser, S. Neser, M. Assmann, S. Srock, R. Rohrberg, K. Dachselt, M. Leithäuser, C.S. Rabkin, M. Herold, and G. Dölken Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients Br J Haematol 141 2008 631 640
16. M. Ladetto, P. Corradini, S. Vallet, F. Benedetti, U. Vitolo, M. Martelli, M. Brugiatelli, P. Coser, A. Perrotti, I. Majolino, G. Fioritoni, S. Morandi, M. Musso, R. Zambello, T. Chisesi, N. Di Renzo, P. Vivaldi, A. De Crescenzo, A. Gallamini, F. Salvi, G. Santini, C. Boccomini, M. Sorio, M. Astolfi, D. Drandi, A. Pileri, and C. Tarella High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO) Blood 100 2002 1559 1565
17. A.S. Freedman, D. Neuberg, P. Mauch, R.J. Soiffer, K.C. Anderson, D.C. Fisher, R. Schlossman, E.P. Alyea, T. Takvorian, H. Jallow, C. Kuhlman, J. Ritz, L.M. Nadler, and J.G. Gribben Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma Blood 94 1999 3325 3333
18. A.S. Baur, P. Shaw, N. Burri, F. Delacrétaz, F.T. Bosman, and P. Chaubert Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas Blood 94 1999 1773 1781
19. Y. Li, H. Nagai, T. Ohno, M. Yuge, S. Hatano, E. Ito, N. Mori, H. Saito, and T. Kinoshita Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype Blood 100 2002 2572 2577
20. D. Rossi, D. Capello, A. Gloghini, S. Franceschetti, M. Paulli, K. Bhatia, G. Saglio, U. Vitolo, S.A. Pileri, M. Esteller, A. Carbone, and G. Gaidano Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia Haematologica 89 2004 154 164
21. C. O'Riain, D.M. O'Shea, Y. Yang, R. Le Dieu, J.G. Gribben, K. Summers, J. Yeboah-Afari, L. Bhaw-Rosun, C. Fleischmann, C.A. Mein, T. Crook, P. Smith, G. Kelly, A. Rosenwald, G. Ott, E. Campo, L.M. Rimsza, E.B. Smeland, W.C. Chan, N. Johnson, R.D. Gascoyne, S. Reimer, R.M. Braziel, G.W. Wright, L.M. Staudt, T.A. Lister, and J. Fitzgibbon Array-based DNA methylation profiling in follicular lymphoma Leukemia 23 2009 1858 1866
22. M.T. Voso, D. Gumiero, F. D'Alo', F. Guidi, G. Mansueto, A.L. Di Febo, G. Massini, M. Martini, L.M. Larocca, S. Hohaus, and G. Leone DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma Haematologica 91 2006 1252 1256
23. S. Agrawal, M. Unterberg, S. Koschmieder, U. zur Stadt, U. Brunnberg, W. Verbeek, T. Büchner, W.E. Berdel, H. Serve, and C. Müller-Tidow DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia Cancer Res 67 2007 1370 1377
24. H. Yang, T. Kadia, L. Xiao, C.E. Bueso-Ramos, K. Hoshino, D.A. Thomas, S. O'Brien, E. Jabbour, S. Pierce, G.L. Rosner, H.M. Kantarjian, and G. Garcia-Manero Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia Blood 113 2009 1892 1898
25. K. Hagiwara, Y. Li, T. Kinoshita, S. Kunishma, H. Ohashi, T. Hotta, and H. Nagai Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma Leuk Res 34 2010 50 54
26. J. Stutterheim, F.A. Ichou, E. den Ouden, R. Versteeg, H.N. Caron, G.A. Tytgat, and C.E. van der Schoot Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma Clin Cancer Res 18 2012 808 814
27. J.J. van Dongen, A.W. Langerak, M. Brüggemann, P.A. Evans, M. Hummel, F.L. Lavender, E. Delabesse, F. Davi, E. Schuuring, R. García-Sanz, J.H. van Krieken, J. Droese, D. González, C. Bastard, H.E. White, M. Spaargaren, M. González, A. Parreira, J.L. Smith, G.J. Morgan, M. Kneba, and E.A. Macintyre Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936 Leukemia 17 2003 2257 2317
28. M.O. Hoque, E. Rosenbaum, W.H. Westra, M. Xing, P. Ladenson, M.A. Zeiger, D. Sidransky, and C.B. Umbricht Quantitative assessment of promoter methylation profiles in thyroid neoplasms [erratum in: J Clin Endocrinol Metab 2006;91:3278] J Clin Endocrinol Metab 90 2005 4011 4018
29. V.H. van der Velden, G. Cazzaniga, A. Schrauder, J. Hancock, P. Bader, E.R. Panzer-Grumayer, T. Flohr, R. Sutton, H. Cave, H.O. Madsen, J.M. Cayuela, J. Trka, C. Eckert, L. Foroni, U. Zur Stadt, K. Beldjord, T. Raff, C.E. van der Schoot, J.J. van Dongen European Study Group on MRD detection in ALL (ESG-MRD-ALL) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data Leukemia 21 2007 604 611
30. A.N. Reddy, W.W. Jiang, M. Kim, N. Benoit, R. Taylor, J. Clinger, D. Sidransky, and J.A. Califano Death-associated protein kinase promoter hypermethylation in normal human lymphocytes Cancer Res 63 2003 7694 7698
31. P. Brice, Y. Bastion, E. Lepage, N. Brousse, C. Haïoun, P. Moreau, N. Straetmans, H. Tilly, I. Tabah, and P. Solal-Céligny Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 15 1997 1110 1117
32. R. Claus, B. Hackanson, A.R. Poetsch, M. Zucknick, M. Sonnet, N. Blagitko-Dorfs, J. Hiller, S. Wilop, T.H. Brümmendorf, O. Galm, U. Platzbecker, J.C. Byrd, K. Döhner, H. Döhner, M. Lübbert, and C. Plass Quantitative analyses of DAPK1 methylation in AML and MDS Int J Cancer 131 2012 E138 E142
33. V.H. van der Velden, E.R. Panzer-Grümayer, G. Cazzaniga, T. Flohr, R. Sutton, A. Schrauder, G. Basso, M. Schrappe, J.M. Wijkhuijs, M. Konrad, C.R. Bartram, G. Masera, A. Biondi, and J.J. van Dongen Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting Leukemia 21 2007 706 713
34. D. Yao, J. Shi, B. Shi, N. Wang, W. Liu, G. Zhang, M. Ji, L. Xu, N. He, and P. Hou Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer Clin Chim Acta 413 2012 787 794
35. K. Rand, W. Qu, T. Ho, S.J. Clark, and P. Molloy Conversion-specific detection of DNA methylation using real-time polymerase chain reaction (ConLight-MSP) to avoid false positives Methods 27 2002 114 120
36. P.G. Gobbi, C. Broglia, G. Di Giulio, M. Mantelli, P. Anselmo, F. Merli, P.L. Zinzani, G. Rossi, V. Callea, E. Iannitto, M. Paulli, L. Garioni, and E. Ascari The clinical value of tumor burden at diagnosis in Hodgkin lymphoma Cancer 101 2004 1824 1834
37. A. Berkowitz, S. Basu, S. Srinivas, S. Sankaran, S. Schuster, and A. Alavi Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET Nucl Med Commun 29 2008 521 526
38. G. Salles, J.F. Seymour, F. Offner, A. López-Guillermo, D. Belada, L. Xerri, P. Feugier, R. Bouabdallah, J.V. Catalano, P. Brice, D. Caballero, C. Haioun, L.M. Pedersen, A. Delmer, D. Simpson, S. Leppa, P. Soubeyran, A. Hagenbeek, O. Casasnovas, T. Intragumtornchai, C. Fermé, M.G. da Silva, C. Sebban, A. Lister, J.A. Estell, G. Milone, A. Sonet, M. Mendila, B. Coiffier, and H. Tilly Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial [erratum in: Lancet. 2011;377:1154] Lancet 377 2011 42 51
39. M. Al Khabori, J.R. de Almeida, G.H. Guyatt, J. Kuruvilla, and M. Crump Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis J Natl Cancer Inst 104 2012 18 28
40. P. Solal-Céligny, M. Bellei, L. Marcheselli, E.A. Pesce, S. Pileri, P. McLaughlin, S. Luminari, B. Pro, S. Montoto, A.J. Ferreri, E. Deconinck, N. Milpied, L.I. Gordon, and M. Federico Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database J Clin Oncol 30 2012 3848 3853
41. L. Lowry, and K.M. Ardeshna Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma? Cancer J 18 2012 390 395